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Background: Pseudomonas aeruginosa with mutations in the transcriptional regulator LasR chronically infect the airways of people with cystic
fibrosis (CF), yet the prevalence and clinical implications of lasR mutant infection are unknown.
Methods: In an exploratory study, we screened 166 P. aeruginosa isolates from 58 CF patients for LasR inactivation and mucoidy, and compared
clinical characteristics among source patients.
Results: lasR mutation prevalence was comparable to that of mucoidy, the best-described CF-adapted phenotype, but affected patients were on
average approximately 2 years younger. In a regression analysis, lung function decline with age was worse among patients with lasR mutant
infection than in those without, similar to the effect of mucoidy.
Conclusions: Culture positivity for lasR mutant P. aeruginosa may serve as a marker of early CF adaptive change of prognostic significance.
Furthermore, as LasR inactivation alters susceptibility to antibiotics, infection with lasR mutant P. aeruginosa may impact response to therapy.
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Microbes that cause chronic infections undergo genetic change
as they adapt to selective pressures encountered in host tissues. For
example, in the chronic airway infection in people with cystic
fibrosis (CF), P. aeruginosa undergoes multiple genetic changes
[1]. The best described of these changes results in the over-
production of exopolysaccharide, or mucoidy (usually due to
mutations in mucA or related genes), a phenotype observed
commonly among CF isolates [2]. Infection with mucoid☆ Some of these data were presented at the 2007 Annual North American
Cystic Fibrosis Foundation Conference in Anaheim, CA, October, 2007.
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doi:10.1016/j.jcf.2008.09.006P. aeruginosa increases in prevalence with advancing age among
CF patients, and is associated with accelerated lung function
decline compared with infection with non-mucoid isolates [3].
Recently, another P. aeruginosa adaptive mutation was
found to occur during CF infections: inactivation of the
transcriptional regulator LasR [1,4–8]. Null mutation of the
lasR gene leads to several phenotypic changes of potential
clinical significance, including a growth advantage in amino
acids abundant in CF airway secretions [8,9]. lasR mutation
leads to a distinctive colony morphology that includes surface
iridescent sheen and colony flattening, the latter due to cell
autolysis (Fig. 1). These colony characteristics facilitate the
identification of lasR mutant isolates [1,8]. lasR mutants also
exhibit increased β-lactamase activity [8]. Furthermore,
quorum sensing blockade by chemical inhibitors (while not
specific for the las system) has been shown to alterd by Elsevier B.V. All rights reserved.
Fig. 1. Characteristic colony morphology identifies lasR mutant P. aeruginosa CF isolates. (A) LB agar-grown colonies of two clonally-related clinical isolates of
P. aeruginosa from a single CF patient, one with an inactivating lasR mutation and the other with wild-type lasR, as indicated. The lasR mutant isolate displays
phenotypes characteristic of lasR mutants, including surface iridescent, metallic sheen, which is particularly evident in this photograph (yellow arrow). (B) Another
pair of LB agar-grown, clonally-related clinical P. aeruginosa isolates in which one isolate has an inactivating lasR mutation that demonstrates colony lysis and
flattening (blue arrow). (C) An LB agar-grown P. aeruginosa isolate that is mucoid and has wild-type LasR protein function, for comparison with (D–E). (D) A
mucoid P. aeruginosa isolate with an inactivating lasR mutation, exhibiting floating, iridescent material (yellow arrow). (E) Another mucoid isolate with inactivating
lasR mutation in which colony lysis is particularly evident (blue arrow).
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mutation could impact both the effectiveness of antibiotic
treatments for CF lung infection and the course of CF lung
disease by resulting in an increased growth rate within the
airway, where amino acids are abundant [9].
Therefore, we hypothesized that infection with lasR mutant
P. aeruginosa is common and resulted in an association with
a more severe course of CF lung disease, similar to the
association with the mucoidy phenotype. To investigate this
hypothesis, we performed an exploratory, cross-sectional,
retrospective investigation of the prevalence of lasR mutant
isolates among children attending the Children's Hospital and
Regional Medical Center (CHRMC) CF clinic in Seattle, and
compared age and lung function values among these patients.
2. Methods
2.1. Isolates and patients
P. aeruginosa isolates were selected at random from the
CHRMC Antimicrobial Toolkit, a large archive of bacteria from
local CF patients maintained for research. Isolates were eligible forselection if obtained from patients who met the following criteria:
attendance at the CHRMC CF clinic during the years 1988–2002,
age 15 years or younger during the study period, documentation of
informed consent for studies involving clinical bacterial isolates
and linked data, and culture positivity for archived P. aeruginosa.
58 patients were selected according to these criteria. Patient age
and, where available, lung function parameters including forced
expiratory volume in 1 s (FEV1) were recorded from the culture
dates on which cultures were performed. Data regarding initial
culture positivity (required to define duration of infection) with P.
aeruginosa were not reliably available for this patient population.
The conduct of this study was approved by the CHRMC Human
Subjects Institutional Review Board (IRB).
2.2. Isolate phenotypic analysis
Each isolate was assigned a study code. Colony surface
iridescent sheen and autolysis were analyzed as described [8],
and mucoidy was identified by standard visual inspection
[2,12], in parallel by three separate microbiologists, including
one clinical microbiologist, all of whom were unaware of the
culture dates or source patient identities.
Table 1
Characteristics of the study population are shown
N (%)
Males 31 (53.5%)
Females 27 (46.5%)
Genotype: ΔF508 homozygous 35 (60.3%)
Genotype: ΔF508 heterozygous a 20 (34.5%)
Genotype: other b 1 (1.7%)
Genotype: missing 2 (3.5%)
Isolates: lasR mutants 52/166 (31%)
Isolates: Mucoid 62/166 (37%)
Isolates: lasR mutant and mucoid 19/166 (11%)
Isolates: lasR wild-type and non-mucoid 71/166 (43%)
Mean (SD) [min, max]
Age (years) at earliest culture date 8.5 (4.2) [0.3, 14.9]
Among patients with FEV1 data available (N=44 patients, 52 culture dates)
Age (years) at earliest culture date 10.6 (2.7) [5.8, 14.7]
FEV1 % predicted at earliest culture date 79.2 (20.9) [27, 127]
The full dataset included 166 P. aeruginosa isolates representing 85 culture
dates and 58 patients.
a Includes 6 patients with one ΔF508 mutation and one mutation that was not
identified. ΔF508 is the CF disease-causing mutation that is most common and
is associated with a relatively severe phenotype [14].
b Includes 1 patient with one non-F508 mutation and one mutation that was
not identified.
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The DNA sequences of the lasR genes from a subset of
isolates were obtained as described [8]. For some isolates, data
from multilocus sequence typing were available from previous
analyses [1].
2.4. Statistical analysis
Data were summarized using descriptive statistics. The
frequencies of detection of isolates displaying mucoidy and/or
the lasR mutant phenotype were determined for the entire
isolate set, and the frequencies of cultures positive for isolates
displaying each phenotype were also described. Mean age of
earliest culture positivity for mucoid or lasR mutant isolates
was calculated for the study population. Linear regression
models were used to examine the cross-sectional relationship
between lung function and age. These models included age-
phenotype interaction terms to allow estimation of separate
slopes for lung function decline with age for each phenotype.
Three separate regression models were fit to the data for patients
from whom concurrent culture and lung function results were
available. In each model, slope and 95% confidence intervals
were estimated for the decline in FEV1 percent predicted for
each year of age. Several patients had cultures available from
two visits; thus, regression models accounted for repeated
observations per patient. If a given culture yielded multiple
P. aeruginosa isolates, the patient was classified as having a
sheen positive (i.e., lasR mutant) or mucoid positive culture for
that date if at least 1 isolate displayed the characteristic of
interest. All analyses were performed using Stata, version 9.1.
3. Results
3.1. Study population and colony phenotypes
We examined 166 P. aeruginosa isolates (from 58 patients;
average 2.8 isolates per patient, range 1–7) randomly selected
from a large archive of isolates collected from young CF
patients during routine clinical care. Characteristics of the study
population are detailed in Table 1; descriptions of the isolates,
their phenotypes, and genotypic information (when available)
are included in Supplemental Table 1. We screened this isolate
collection for colony surface iridescent, metallic sheen, a
phenotype that specifically identifies lasR mutation, including
in the presence of mucoidy [8] (Fig. 1). We confirmed this
100% predictive relationship by fully sequencing lasR from 17
sheen-positive and 44 sheen-negative isolates (of which 9 and
25 were mucoid, respectively— results shown in Supplemental
Table 1). Therefore, isolates with sheen will hereafter be
referred to as “lasR mutant”, while those without sheen will be
referred to as “lasR wild-type”. The presence or absence of
mucoidy (which is not caused by lasR mutation) was also
described for each isolate. Colony phenotypes were described
independently by three researchers; in cases of disagreement
regarding phenotypes, the majority decision prevailed. All three
observers agreed on the presence of sheen, indicative of LasRinactivation, or its absence for 98% of isolates, and on the
presence or absence of mucoidy for 96% of isolates. In this
collection, the presence of sheen was observed among 52 of 166
(31%) isolates, a prevalence comparable to that we observed for
mucoidy (62 of 166 isolates, or 37%).
The lasR sequencing data in Supplemental Table 1, coupled
with multilocus sequence typing analysis of a subset of these
isolates described previously [1] and the wide diversity of plate
phenotypes of lasR mutants studied (not shown) indicated that
lasR mutant isolates among this population did not represent a
single, clonal (epidemic) strain of P. aeruginosa.
3.2. Age of source patients with specific isolates
Using the earliest positive culture per patient, average age at
culture positivity for lasR mutant isolates was 9.2 years (SD
4.4), slightly younger than the 11.0 years (SD 3.5) we observed
for mucoidy. These results suggest that lasR mutation may arise
earlier than mucoidy during adaptation to CF airways.
3.3. Impact of LasR inactivation on lung function
We then performed an exploratory analysis of the relationship
between lung function (indicated by forced expiratory volume in
1 s, FEV1) and age using linked clinical data for all patients for
whom such data were available (44 patients, 52 cultures, 105
isolates). We sought to determine how this relationship differed
according to patients' lasR or mucoidy status on a given culture
date. The 52 culture dates analyzed included 35 cultures with
only lasR wild-type isolates and 17 cultures with lasR mutant
isolates detected. As shown in Table 2, the presence of infection
with lasR mutant P. aeruginosa isolates was associated with a
statistically significant negative slope for FEV1 percent
predicted versus age, in contrast to the slope for presence of
Table 2
Slopes, 95% confidence intervals, and P-values computed from regression
models for the relationship between FEV1 percent predicted and age according
to culture phenotype status as shown
Group Slope (decline in FEV1%
predicted per year of age)
95% CI
for slope
P-value
lasR mutant a
P. aeruginosa
−4.1 (−7.0, −1.2) 0.006
lasR wild-type a
P. aeruginosa
−2.3 (−4.6, −0.02) 0.05
Mucoid P. aeruginosa −4.0 (−6.1, −1.9) b0.001
Non-mucoid
P. aeruginosa
−0.3 (−2.7, 2.1) 0.80
All subjects combined −2.9 (−4.5, −1.3) 0.001
Results were not corrected for multiple comparisons.
a Colony surface sheen was used as a surrogate marker for LasR inactivation
[8].
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to the slope for the entire collection. This difference in slopes
was similar to that calculated for the presence of mucoid isolates
relative to the presence of only non-mucoid isolates (Table 2).
One potential explanation for the difference in the slopes for
cultures with lasR wild-type isolates, when compared with
cultures with non-mucoid isolates, was a higher co-prevalence of
mucoidy among lasR wild-type cultures (67%) compared to a
lower co-prevalence of lasR mutants among non-mucoid
cultures (33%).
4. Discussion
Our results suggest that lasR inactivation may be associated
with progression of CF lung disease, similar to mucoidy [3], and
may represent an earlier marker of poor prognosis. lasR mutant
P. aeruginosa isolates have been observed from diverse clinical
sources [10], including endotracheal tubes [13], and among CF
patients from North America [1,8,22], Europe [21], and
Australia [5,7]. In one retrospective study of isolates collected
longitudinally from 30 CF patients in Seattle, lasR mutant
isolates were found to have emerged independently among 19
(63%), in many cases without the identification of concurrent
wild-type isolates. In several instances, multiple lasR mutations
were found in the same isolates, suggesting strong selective
pressure for loss of LasR function within CF airways [1,8].
Despite the considerable prevalence of lasR mutant isolates
among CF patients, the clinical impact of these infections was
not previously studied. (While our study could not establish a
causal relationship between lasR mutant infection and clinical
course, these results suggest that lasR mutation is at least
associated with lung disease progression.) Laboratory analyses
demonstrated that lasR mutant isolates exhibit at least two
phenotypes in vitro that could negatively impact clinical course:
they have a growth advantage using specific amino acids, such
as phenylalanine, that are known to be abundant in CF
secretions [8,9], and they are also relatively tolerant to β-
lactam antibiotics used frequently in CF therapy, including
ceftazidime [14], due to increased β-lactamase activity relative
to their wild-type counterparts in all genetic backgrounds testedto date ([8] and data not shown). Unfortunately, our clinical
database did not contain sufficient information regarding
preceding or concurrent antibiotic treatments to examine
whether patients with lasR mutant isolates were either more
likely to have received ceftazidime or other β-lactam antibiotics
prior to isolation, or whether they responded less well to such
therapies, than did patients without lasR mutants. Regardless,
these two characteristics–antibiotic resistance and high growth
yield in abundant host nutrients–may help to explain the
association between poor clinical course and lasR mutant
infection among CF patients shown in Table 2, despite the fact
that inactivating mutation in lasR would also be predicted to
decrease expression of some characteristics associated with
acute virulence [15]. It should be noted that some LasR-
dependent products and phenotypes traditionally associated
with virulence, including protease secretion and biofilm
formation, were shown to be intact among many lasR mutant
clinical isolates, suggesting that these functions may have
become uncoupled from LasR regulation [5,13,22]. Another
characteristic of lasR mutant isolates that may be of clinical
significance is their relatively high susceptibility to amino acid-
based metabolic inhibitors, including fluorophenylalanine [8].
This quality could be exploited to design targeted therapies
when lasR mutant isolates are identified in clinical specimens.
The presence of lasR inactivating mutations was easily
identifiable by screening for the unique colony sheen
phenotype. We found that inter-observer reproducibility for
sheen was at least as good, and likely better, than it was for
mucoidy, a colony morphotype that is currently reported by
clinical microbiological laboratories due to its association with
poor prognosis [2,3]. Thus, the identification of lasR mutants is
feasible for most clinical laboratories, and may be of both
prognostic and therapeutic significance.
Our results suggest that lasR mutation may arise earlier than
mucoidy, indicative of an early adaptation to the CF airway.
Current CF treatment strategies focus on early eradication of
P. aeruginosa upon initial culture positivity [14], driven in large
part by the observation that adaptation of P. aeruginosa to the
CF airway, including the development of mucoidy, is associated
with a worse prognosis and recalcitrance to eradication [2,3].
Given the relative resistance of lasR mutants to β-lactam
antibiotics [8], the current results further support this early
treatment strategy. Furthermore, these observations suggest that
regimens that include a β-lactamase inhibitor may be
particularly beneficial upon culture positivity for lasR mutants.
Therefore, the identification of bacterial characteristics (such as
colony sheen) may prove useful in directing therapy.
Our study is limited by its retrospective and cross-sectional
nature, as well as the availability of lung function data from a
limited subset of study patients. Furthermore, while duration of
infection (as opposed to patient age) has been associated with
the emergence of mucoidy and CF lung function change [16],
we have used patient age at isolation instead because data
regarding the dates of initial culture positivity for P. aeruginosa
(and thus duration of infection for the currently studied cultures)
were not reliably available for this study population. In support
of this approach, recent work demonstrated that culture may be
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[17–19]. Regardless, the utility of lasR mutation, indicated by
the easily identifiable sheen phenotype, as a predictor of lung
disease progression should be validated in a well-designed,
prospective study, preferably at multiple sites. The optimal
study would also be longitudinal, in order to investigate the
evolution of lung disease severity before and after isolation of
lasR mutants. Such a study would also be useful in identifying
clinical factors, such as antecedent antibiotic treatments, that are
associated with the emergence of lasR mutant isolates. If the
current results are validated in such a prospective study, the
clinical identification of lasR mutant P. aeruginosa isolates
from CF patients could represent a significant advance in CF
clinical microbiology, perhaps with utility higher than that for
either antibiotic susceptibility testing [20] or the identification
of mucoidy (3).
Acknowledgments
This work was supported by grants from the NIH
(1KO8AI066251 and 5R01DK064954) and the Cystic Fibrosis
Foundation (HOFFMA04L0, BURNS03Y2 and MILL-
ER07PO). We gratefully acknowledge Anne Marie Buccat for
technical assistance and Ronald Gibson for editorial assistance.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.jcf.2008.09.006.
References
[1] Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR,
D'Argenio DA, et al. Genetic adaptation by Pseudomonas aeruginosa to
the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A May 30
2006;103(22):8487–92.
[2] Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev
1996;60(3):539–74.
[3] Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al.
Longitudinal development of mucoid Pseudomonas aeruginosa infection
and lung disease progression in children with cystic fibrosis. Jama Feb 2
2005;293(5):581–8.
[4] Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C.
Widespread pyocyanin over-production among isolates of a cystic fibrosis
epidemic strain. BMC Microbiol 2007;7:45.
[5] Tingpej P, Smith L, Rose B, Zhu H, Conibear T, Al Nassafi K, et al.
Phenotypic characterization of clonal and nonclonal Pseudomonas
aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin
Microbiol Jun 2007;45(6):1697–704.
[6] Heurlier K, Denervaud V, Haenni M, Guy L, Krishnapillai V, Haas D.
Quorum-sensing-negative (lasR) mutants of Pseudomonas aeruginosa
avoid cell lysis and death. J Bacteriol Jul 2005;187(14):4875–83.[7] Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R,
Griswold JA, et al. Analysis of quorum sensing-deficient clinical isolates
of Pseudomonas aeruginosa. J Med Microbiol Sep 2004;53(Pt 9):841–53.
[8] D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Deziel E, Smith EE,
et al. Growth phenotypes of Pseudomonas aeruginosa lasR mutants
adapted to the airways of cystic fibrosis patients. Mol Microbiol Apr
2007;64(2):512–33.
[9] Barth AL, Pitt TL. The high amino-acid content of sputum from cystic
fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa.
J Med Microbiol Aug 1996;45(2):110–9.
[10] Cabrol S, Olliver A, Pier GB, Andremont A, Ruimy R. Transcription of
quorum-sensing system genes in clinical and environmental isolates of
Pseudomonas aeruginosa. J Bacteriol Dec 2003;185(24):7222–30.
[11] Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen
HP, et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen
peroxide and polymorphonuclear leukocytes is quorum-sensing depen-
dent. Microbiology Feb 2005;151(Pt 2):373–83.
[12] Burns JL,VanDalfsen JM, ShawarRM,OttoKL,Garber RL, Quan JM, et al.
Effect of chronic intermittent administration of inhaled tobramycin on
respiratory microbial flora in patients with cystic fibrosis. J Infect Dis
1999;179(5):1190–6.
[13] Denervaud V, TuQuoc P, Blanc D, Favre-Bonte S, Krishnapillai V,
Reimmann C, et al. Characterization of cell-to-cell signaling-deficient
Pseudomonas aeruginosa strains colonizing intubated patients. J Clin
Microbiol Feb 2004;42(2):554–62.
[14] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of
pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med Oct 15
2003;168(8):918–51.
[15] Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al.
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing
inhibitors. Embo J Aug 1 2003;22(15):3803–15.
[16] Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection
with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax Jan
1992;47(1):6–13.
[17] Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al.
Longitudinal assessment ofPseudomonas aeruginosa in young children with
cystic fibrosis. J Infect Dis Feb 1 2001;183(3):444–52.
[18] West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al.
Respiratory infections with Pseudomonas aeruginosa in children with
cystic fibrosis: early detection by serology and assessment of risk factors.
Jama 2002;287(22):2958–67.
[19] da Silva Filho LV, Tateno AF, Martins KM, Azzuz Chernishev AC, Garcia
Dde O, Haug M, et al. The combination of PCR and serology increases the
diagnosis of Pseudomonas aeruginosa colonization/infection in cystic
fibrosis. Pediatr Pulmonol Oct 2007;42(10):938–44.
[20] Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Suscept-
ibility testing of Pseudomonas aeruginosa isolates and clinical response to
parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest May 2003;123(5):1495–502.
[21] Salunkhe P, Smart CH,Morgan JA, Panagea S,WalshawMJ,Hart CA, et al. A
cystic fibrosis epidemic strain ofPseudomonas aeruginosa displays enhanced
virulence and antimicrobial resistance. J Bacteriol Jul 2005;187(14):
4908–20.
[22] Schaber JA, CartyNL,McDonaldNA,GrahamED,CheluvappaR,Griswold
JA, et al. Analysis of quorum sensing-deficient clinical isolates of
Pseudomonas aeruginosa. J Med Microbiol Sep 2004;53(Pt 9):841–53.
